- $13.53bn
- $10.45bn
- $3.12bn
- 93
- 68
- 69
- 91
Annual income statement for Genmab A/S, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | fx Final | fx Final | fx Final |
| Revenue | |||||
| Total Revenue | 1,546 | 1,338 | 2,050 | 2,391 | 3,122 |
| Cost of Revenue | |||||
| Gross Profit | — | 1,338 | 2,050 | 2,358 | 2,979 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 581 | 869 | 1,164 | 1,619 | 2,150 |
| Operating Profit | 965 | 470 | 886 | 772 | 972 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 903 | 623 | 982 | 818 | 1,329 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 728 | 470 | 771 | 632 | 1,138 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 728 | 470 | 771 | 632 | 1,138 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 728 | 470 | 771 | 632 | 1,138 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 11.1 | 7.12 | 11.7 | 9.58 | 18.3 |
| Dividends per Share |